MRK
$76.36
Merck &
$.78
1.03%
MRK
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  $1.58
Revenue:  $12.62 Bil
Thursday
Jul 29
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, April 29, 2021

What do you expect when MRK reports earnings?
Beat
Meet
Miss

Where is MRK's stock price going from here?
Up
Flat
Down
Stock chart of MRK
Analysts
Summary of analysts' recommendations for MRK
Score
Grade
Pivots
Resistance
$76.75
$76.51
$76.04

$75.80

Support
$75.33
$75.09
$74.62
Tweet
Growth
Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Peers
InterCeptVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbPfizerUltragenyx PharmaceuticalRegeneron PharmaceuticalsZoetisEli LillyJohnson & Johnson